The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for olaparib (AstraZeneca Pty Ltd)
Active ingredients
olaparib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the maintenance treatment of patients with newly diagnosed BRCA-mutated advanced ovarian cancer.
Therapeutic area
Oncology